Open-access Gastric neuroendocrine tumors: a comprehensive analysis of clinicopathological characteristics and survival outcomes from a reference center

Tumores neuroendócrinos gástricos: análise das características clinicopatológicas e resultados de sobrevida de centro de referência

Background:  Gastric neuroendocrine tumors (gNETs) are uncommon neoplasms arising from enterochromaffin-like cells, representing a distinct subset of gastric malignancies, with challenging clinical management.

Aims:  To analyse the classification, treatment indication, and survival of patients diagnosed with gNETs.

Methods:  We retrospectively analyzed patients diagnosed with gNETs between 2009 and 2025 at a high-volume tertiary center in Brazil. Clinical, pathological, and treatment data were reviewed, and tumors were classified according to World Health Organization and clinicopathological criteria into Types I, II, and III.

Results:  Of the 75 patients included, 53 (70.7%) were classified as Type I, 5 (6.7%) as Type II, and 17 (22.6%) as Type III. Treatment included surgery in 25 patients (33.3%) and endoscopic resection in 50 (66.7%). Type I tumors predominated in females (p<0.001), were frequently multifocal (p<0.001), associated with higher body mass index (p=0.002), and were mainly managed endoscopically (p=0.008). Type II tumors were rare and associated with multiple endocrine neoplasia Type 1, while Type III tumors were predominantly male, larger, high-grade (G3), and frequently metastatic, requiring surgical resection and palliative therapy. Among the 25 surgically treated patients, most were men (52%) and included 12 patients (48.0%) with Type I, 3 (12.0%) with Type II, and 10 (40.0%) with Type III tumors. Survival analysis showed significantly worse outcomes for Type III and G3 tumors. Multivariable analysis identified advanced age (hazards ratio 4.11; 95% confidence interval (95%CI): 1.14–14.80; p=0.030) and tumor, lymph node, metastasis (TNM) stage III/IV (HR 5.42; 95%CI: 1.26–23.26; p=0.023) as independent predictors of poorer survival.

Conclusions:  gNETs exhibit heterogeneous clinical behavior, with Type I tumors predominating in the Brazilian population. Tumor type, grade, and TNM stage are critical determinants of prognosis and should guide individualized treatment strategies.

Headings:
Stomach neoplasms; Neuroendocrine tumors; Gastrectomy; Survival analysis; Endoscopy

In one of the largest Brazilian gNET series, Type I tumors predominated, showing an indolent course and endoscopic management, while Type III was aggressive, high-grade, and frequently metastatic.

Advanced age and TNM stage III/IV were identified as the strongest independent predictors of poorer overall survival, highlighting the importance of early detection.

Our findings reinforce that accurate tumor classification by type and grade is essential to guide individualized treatment strategies, optimizing the prognosis for gNET patients.

CENTRAL MESSAGE  The stomach is the most frequent site of gastrointestinal neuroendocrine neoplasms (NENs), with an annual incidence of approximately 0.4 per 1,00,000 individuals. According to the most recent World Health Organization Classification of Tumors of the Digestive System, NENs are divided into three major categories: gastric neuroendocrine tumors, which are the most common, well-differentiated, and have any grade; neuroendocrine carcinomas, which are poorly differentiated and high-grade; and mixed neuroendocrine-non-neuroendocrine neoplasms, which are aggressive and harbor multiple molecular alterations. These neoplasms originate from enterochromaffin-like cells of the gastric mucosa.

PERSPECTIVES  Gastric neuroendocrine tumors (gNETs) are uncommon and heterogeneous, and require individualized management. In this largest Brazilian cohort, Type I gNET predominated, showing indolent behavior and favorable outcomes with endoscopic treatment. Type II tumors were rare and invariably linked to multiple endocrine neoplasia type 1, while Type III tumors presented aggressive features, advanced stage, and poor survival. Prognosis was strongly determined by tumor, lymph node, metastasis stage, highlighting the importance of accurate staging and histopathological evaluation.


location_on
Colégio Brasileiro de Cirurgia Digestiva Av. Brigadeiro Luiz Antonio, 278 - 6° - Salas 10 e 11, 01318-901 São Paulo/SP Brasil, Tel.: (11) 3288-8174/3289-0741 - São Paulo - SP - Brazil
E-mail: revistaabcd@gmail.com
rss_feed Acompanhe os números deste periódico no seu leitor de RSS
Ir para o topo Reportar erro